CONSISTENT BENEFIT OF DAPAGLIFLOZIN ACCORDING TO BACKGROUND THERAPY IN PATIENTS WITH HFREF: AN ANALYSIS OF THE DAPA-HF TRIAL

In DAPA-HF, dapagliflozin (10mg qd) compared with placebo, reduced the risk of worsening HF and CV death. It is important to understand whether the effects of dapagliflozin vary according to background HF therapy. Key inclusion criteria: 1) NYHA class II-IV, 2) LVEF ≤40%, and 3) elevated plasma